Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Abstract Background Treatment of hepatocellular carcinoma (HCC) varies widely depending on the patient's condition. In recent years, combination therapy with immune checkpoint inhibitors has emerged as the treatment of choice due to its superior antitumor effects for unresectable HCC (uHCC). Convers...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ryosuke Tsunemitsu, Motoyasu Tabuchi, Shinya Sakamoto, Kenta Ogi, Manabu Matsumoto, Jun Iwata, Takehiro Okabayashi
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Japan Surgical Society 2023-06-01
Schriftenreihe:	Surgical Case Reports
Schlagworte:	Advanced hepatocellular carcinoma Conversion surgery Atezolizumab plus bevacizumab
Online-Zugang:	https://doi.org/10.1186/s40792-023-01678-9
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!